Home›Trial›NCT07108894
NCT07108894Phase 1RECRUITING

A First-in-Human Phase 1 Single-Ascending Dose Study of ABCL575 in Healthy Participants

Study Summary

This study aims to assess the safety and tolerability of ABCL575 in healthy participants following single ascending dose (SAD), in comparison to a placebo

Conditions
Healthy Volunteers
Interventions / Drugs
ABCL575Placebo (Normal Saline 0.9%)
View on ClinicalTrials.gov ↗
Sponsor
ABCL
AbCellera Biologics
Antibody Discovery
C55/100
Study Details
Enrollment40 participants
Primary Completion—
Lead SponsorAbCellera Biologics Inc.
Data Retrieved2026-04-11 02:51:52.778521+00:00
What This Trial Means for Biotech Investors
Trial Phase Context

Phase 1 trials primarily test safety and dosing in a small number of participants (typically 20–100). Results do not yet speak to efficacy. FDA approval is typically many years away from this stage.

Status & Expected Data

Currently recruiting: the trial is enrolling patients. A data readout is not expected until after enrollment closes and the follow-up period is complete.

Enrolled: 40 participants
Sponsor Catalyst Profile

AbCellera Biologics (ABCL) is the sponsoring company for this trial. BiotechSign currently grades this company C (55/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

ABCL Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.